These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 36790596)

  • 21. Prevalence of diabetes and hypertension and their interaction effects on cardio-cerebrovascular diseases: a cross-sectional study.
    Wang Z; Yang T; Fu H
    BMC Public Health; 2021 Jun; 21(1):1224. PubMed ID: 34172039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Current and Potential Therapeutic Use of Metformin-The Good Old Drug.
    Drzewoski J; Hanefeld M
    Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33562458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 9. Pharmacologic Approaches to Glycemic Treatment:
    American Diabetes Association
    Diabetes Care; 2021 Jan; 44(Suppl 1):S111-S124. PubMed ID: 33298420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypertension Prevalence Among Adults Aged 18 and Over: United States, 2017-2018.
    Ostchega Y; Fryar CD; Nwankwo T; Nguyen DT
    NCHS Data Brief; 2020 Apr; (364):1-8. PubMed ID: 32487290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects.
    Yi L; Zhang H; Zhang JW; You XM; Ning ZQ; Yu J; Qian LF; Miao LY
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):934-941. PubMed ID: 30809967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. National Trends in Diabetes Medication Use in the United States: 2008 to 2015.
    Raval AD; Vyas A
    J Pharm Pract; 2020 Aug; 33(4):433-442. PubMed ID: 30572757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
    Bogman K; Schwab D; Delporte ML; Palermo G; Amrein K; Mohr S; De Vera Mudry MC; Brown MJ; Ferber P
    Hypertension; 2017 Jan; 69(1):189-196. PubMed ID: 27872236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects.
    Yamazaki T; Desai A; Goldwater R; Han D; Lasseter KC; Howieson C; Akhtar S; Kowalski D; Lademacher C; Rammelsberg D; Townsend R
    Clin Pharmacol Drug Dev; 2017 Jan; 6(1):66-75. PubMed ID: 27273004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus.
    Iglay K; Hannachi H; Joseph Howie P; Xu J; Li X; Engel SS; Moore LM; Rajpathak S
    Curr Med Res Opin; 2016 Jul; 32(7):1243-52. PubMed ID: 26986190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers.
    Morrissey KM; Stocker SL; Chen EC; Castro RA; Brett CM; Giacomini KM
    Clin Pharmacokinet; 2016 Apr; 55(4):495-506. PubMed ID: 26507723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological treatment of aldosterone excess.
    Deinum J; Riksen NP; Lenders JW
    Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Comprehensive Review of Drug-Drug Interactions with Metformin.
    Stage TB; Brøsen K; Christensen MM
    Clin Pharmacokinet; 2015 Aug; 54(8):811-24. PubMed ID: 25943187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldosterone synthase inhibitors in hypertension: current status and future possibilities.
    Hargovan M; Ferro A
    JRSM Cardiovasc Dis; 2014 Jan; 3():2048004014522440. PubMed ID: 24570839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics.
    Yonezawa A; Inui K
    Br J Pharmacol; 2011 Dec; 164(7):1817-25. PubMed ID: 21457222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.
    Chen Y; Li S; Brown C; Cheatham S; Castro RA; Leabman MK; Urban TJ; Chen L; Yee SW; Choi JH; Huang Y; Brett CM; Burchard EG; Giacomini KM
    Pharmacogenet Genomics; 2009 Jul; 19(7):497-504. PubMed ID: 19483665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The incidence and implications of aldosterone breakthrough.
    Bomback AS; Klemmer PJ
    Nat Clin Pract Nephrol; 2007 Sep; 3(9):486-92. PubMed ID: 17717561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aldosterone and end-organ damage.
    Marney AM; Brown NJ
    Clin Sci (Lond); 2007 Sep; 113(6):267-78. PubMed ID: 17683282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.
    Tanihara Y; Masuda S; Sato T; Katsura T; Ogawa O; Inui K
    Biochem Pharmacol; 2007 Jul; 74(2):359-71. PubMed ID: 17509534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects.
    Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
    Am J Cardiovasc Drugs; 2023 May; 23(3):277-286. PubMed ID: 36790596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.
    Awosika A; Cho Y; Bose U; Omole AE; Adabanya U
    Expert Opin Investig Drugs; 2023; 32(11):985-995. PubMed ID: 37883217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.